Irisin vs Insulin Aspart
Head-to-head comparison of Irisin (Irisin (FNDC5 cleavage product)) and Insulin Aspart (Insulin aspart (B28-Asp human insulin analog)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Irisin | Insulin Aspart |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Irisin (FNDC5 cleavage product) | Insulin aspart (B28-Asp human insulin analog) |
| Molecular Weight | ~12.3 kDa | 5825.8 Da |
| Half-Life | hours | About 1-3 hours |
| Amino Acids | 112 | 51 |
| Typical Dose | No approved human dose; research use only | 0.05-0.2 U/kg per meal |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 79 | 11000 |
| Research Status | Pre-clinical | Approved |
Irisin Benefits
- ✓glucose homeostasis
- ✓energy expenditure
- ✓brown-fat activation
Insulin Aspart Benefits
- ✓Fast post-meal glucose lowering
- ✓Predictable onset
- ✓Flexible mealtime administration
- ✓Compatible with pump therapy
Irisin Dosing
not established|not established
Insulin Aspart Dosing
Inject SC immediately before meals|Titrate using glucose monitoring and carbohydrate intake|Can be used in insulin pumps or basal-bolus regimens
Irisin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Insulin Aspart Side Effects
- ⚠Hypoglycemia
- ⚠Injection-site reactions
- ⚠Weight gain
Research Overview
Irisin
Irisin is widely explored in obesity and type 2 diabetes research because it connects exercise biology with metabolic adaptation. Human findings are mixed, so it remains a biomarker and preclinical lead rather than an approved therapy.
Insulin Aspart
Research consistently shows faster onset and earlier peak action than regular human insulin. It is commonly studied for meal-time glycemic control and pump-based insulin delivery.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.